What exactly did Leerink say about ELDN on March 16, 2026?

Leerink Partners reiterated an **Outperform** rating on Eledon Pharmaceuticals, Inc. (ELDN) on March 16, 2026. The note did not include a fresh price target and produced a **0.55% ($0.02)** market move.

How should investors interpret the maintained ELDN analyst rating?

A maintained ELDN analyst rating signals continued confidence from the analyst without new conviction from updated valuation. Holders may view it as supportive; new buyers should check pipeline timing and financials before opening positions.

Did the Leerink note change the ELDN price target?

No. The March 16, 2026 Leerink note reiterated Outperform without publishing a new ELDN price target, leaving price guidance unchanged in that update.

How does Meyka AI view ELDN after this rating?

Meyka AI rates ELDN with a grade of B. That grade reflects S&P comparison, sector performance, growth metrics, and analyst consensus, including Leerink’s maintained Outperform.

Analyst Ratings

Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026

ByDanny Kontos March 17, 2026March 17, 2026

Leerink Partners reiterated an Outperform rating on Eledon Pharmaceuticals, Inc. (ELDN) on March 16, 2026, keeping its view steady in the latest note. The firm left the recommendation unchanged, a move reflected in a market price uptick of 0.55% ($0.02) on the report. The ELDN analyst rating remains important because Leerink is a recognized biopharma analyst with recurring coverage on small-cap clinical-stage names. Meyka AI’s real-time data flagged this maintained rating for investors tracking momentum and consensus shifts.